(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]-phenanthrene-6b-carbothioic acid S-fluoromethyl ester trifluoroacetate | 1323943-89-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]-phenanthrene-6b-carbothioic acid S-fluoromethyl ester trifluoroacetate
• 英文别名: S-(fluoromethyl) (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-8-carbothioate;2,2,2-trifluoroacetic acid
• CAS: 1323943-89-0
• 化学式: C₂HF₃O₂*C₃₀H₃₃ClF₃NO₃S
• 分子量: 694.135
• InChiKey: DDKAEWQJEYKCIL-NKQYAAHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.51
• 重原子数：
  46
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4-aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester hydrochloride 在 N-甲基吗啉 、 sodium hydrogensulfide 、 silver fluoride 、 三乙胺 、 sodium iodide 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 79.5h， 生成 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]-phenanthrene-6b-carbothioic acid S-fluoromethyl ester trifluoroacetate
  参考文献：
  名称：

  Novel Pyrrolidine Derivatives of Budesonide as Long Acting Inhaled Corticosteroids for the Treatment of Pulmonary Inflammatory Diseases

  摘要：

  Inhaled corticosteroids (ICSs) represent the first line therapy for the treatment of asthma and are also extensively utilized in chronic obstructive pulmonary disease. Our goal was to develop a new ICS with a basic group, which can allow solid state feature modulation, achieving at the same time high local anti-inflammatory effect and low systemic exposure. Through a rational drug design approach, a new series of pyrrolidine derivatives of budesonide was identified. Within the series, several compounds showed nanomolar binding affinity (K-i) with GR that mostly correlated with the effect in inducing GR nuclear trans location in CHO cells and anti-inflammatory effects in macrophagic cell lines. Binding and functional cell-based assays allowed identifying compound 17 as a potent ICS agonist with a PK profile showing an adequate lung retention and low systemic exposure in vivo. Finally, compound 17 proved to be more potent than budesonide in a rat model of acute pulmonary inflammation.

  DOI：

  10.1021/acs.jmedchem.7b01873

文献信息

• PYRROLIDINE DERIVATIVES
  申请人：GHIDINI Eleonora

  公开号：US20110201580A1

  公开（公告）日：2011-08-18

  The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.

  本发明涉及新型糖皮质激素系列的抗炎和抗过敏化合物，制备此类化合物的方法，包含它们的药物组合物，它们的组合和治疗用途。更具体地，本发明涉及吡咯烷衍生物的糖皮质激素。
• US8481517B2
  申请人：——

  公开号：US8481517B2

  公开（公告）日：2013-07-09